GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » Gross Profit

ABL Bio (XKRX:298380) Gross Profit : ₩32,955 Mil (TTM As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is ABL Bio Gross Profit?

ABL Bio's gross profit for the three months ended in Jun. 2024 was ₩8,442 Mil. ABL Bio's gross profit for the trailing twelve months (TTM) ended in Jun. 2024 was ₩32,955 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. ABL Bio's gross profit for the three months ended in Jun. 2024 was ₩8,442 Mil. ABL Bio's Revenue for the three months ended in Jun. 2024 was ₩8,442 Mil. Therefore, ABL Bio's Gross Margin % for the quarter that ended in Jun. 2024 was N/A%.

ABL Bio had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage


ABL Bio Gross Profit Historical Data

The historical data trend for ABL Bio's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio Gross Profit Chart

ABL Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial 3,988.96 8,104.20 5,332.07 67,300.80 65,547.06

ABL Bio Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,590.31 8,570.73 8,004.70 7,937.21 8,441.93

Competitive Comparison of ABL Bio's Gross Profit

For the Biotechnology subindustry, ABL Bio's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABL Bio's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ABL Bio's Gross Profit distribution charts can be found below:

* The bar in red indicates where ABL Bio's Gross Profit falls into.



ABL Bio Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

ABL Bio's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=65547.055 - 0
=65,547

ABL Bio's Gross Profit for the quarter that ended in Jun. 2024 is calculated as

Gross Profit (Q: Jun. 2024 )=Revenue - Cost of Goods Sold
=8441.926 - 0
=8,442

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩32,955 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

ABL Bio's Gross Margin % for the quarter that ended in Jun. 2024 is calculated as

Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=8,442 / 8441.926
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


ABL Bio  (XKRX:298380) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

ABL Bio had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage


ABL Bio Gross Profit Related Terms

Thank you for viewing the detailed overview of ABL Bio's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


ABL Bio Business Description

Traded in Other Exchanges
N/A
Address
2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio Headlines

No Headlines